10149695QUINETIC - Quantum-based Identification of NEw Targets In CardiomyopathyActiveCollaborative R&DInnovate UKHypertrophic cardiomyopathy (HCM) is a hereditary heart condition that affects approximately 1 in 500 individuals in the UK and Germany. Often leading to significant health challenges and an increased risk of sudden cardiac events, despite its prevalence, current treatment options are limited, and there is an urgent need to support the development of innovative, new therapeutic approaches. To help address this, UK SME CardiaTec and German SME innoVitro GmbH have embarked on a collaborative project to help improve HCM treatment. This project brings together CardiaTec's expertise in artificial intelligence (AI) and quantum computing with innoVitro's advanced cellular modelling capabilities and aims to identify new therapeutic targets for HCM by analysing complex biological networks using quantum algorithms and validating these findings through cutting-edge laboratory techniques. The project will begin by using quantum computing to analyse complex biological networks associated with HCM, identifying key areas that may contribute to the disease. These findings will then be tested in laboratory settings using human heart cells engineered to exhibit HCM characteristics. This approach ensures that the research is directly relevant to human health. Combining cutting-edge technology with biological expertise, this partnership seeks to uncover new pathways for treatment, offering hope to those affected by HCM and will unlock new markets and revenue opportunities in both geographic markets, crystallising a high-value collaboration. By focussing on drug targets already targeted by in-licencable clinical compounds which have failed later stage clinical trials in other indications (due to being applied in an incompatible disease are), but which have passed phase 1 clinical trials (and are therefore safe in humans) will progress CardiaTec rapidly towards treating patients in the clinic, and lead to a huge value inflection for the company.